ClinicalTrials.gg
CompletedNCT04466904Updated Jul 23, 2021

Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

A Phase 1/2 interventional study of IBI362 and Placebo in Type 2 Diabetes, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-23.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
632nd of 767
42 · median 199
Started
2020
with 49 others
Phase 1/2
20 of 909
4 open now
Registered
427th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 632nd largest by enrollment of the 767 interventional ones that give a count, is one of 50 that started in 2020, is one of 20 in phase 1/2, and was the 427th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This trial is aimed to investigate the safety, tolerability, PK and PD of multiple subcutaneous injections of IBI362 in Chinese patients with type 2 diabetes who have poor glycemic control after lifestyle or metformin intervention

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled trial, the first trial to assess the safety, tolerability, and PK/PD of IBI362 administered as multiple injections in Chinese patients with type 2 diabetes. The investigators and subjects will be blinded to the study drug IBI362 and placebo. Dulaglutide will be used as an open-label active control group. In this trial, 42 eligible patients will be recruited and randomly allocated to three cohorts. Each corhot will be randomized as an 8:4:2 ratio to IBI362 (n = 8), placebo (n = 4), and Dulaglutide 1.5 mg (n = 2).

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

* Eligibility Criteria: Inclusion Criiteria:

  1. Male or female 18 to 75 years of age at the time of consent.
  2. T2D patients with poorly controlled blood glucose treated with lifestyle intervention or stable dose of metformin (≥ 1000mg/day or maximum tolerated dose) within 2 months prior to screening.
  3. 7.5% ≤ 11.0% by local laboratory at screening.
  4. 20 ≤ BMI ≤ 35 kg/m2.

Exclusion Criteria:

  1. Type 1 diabetes, special types of diabetes, or gestational diabetes.
  2. Ketoacidosis or lactic acidosis within 6 months prior to screening.
  3. History of severe hypoglycaemic episodes within 6 months prior to screening.
  4. Acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting, coronary intervention (except diagnostic angiography), (TIA), cerebrovascular accident, acute and chronic heart failure within 6 months before screening.
  5. Clinically symptomatic liver disease, acute or chronic hepatitis, or transaminases ( and AST) and alkaline phosphatase (ALP) > 2 times the and total above the upper limit of normal at screening.
  6. The patient was previously diagnosed with autonomic neuropathy, manifested as urinary retention, resting tachycardia, orthostatic hypotension and diabetic diarrhea.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    IBI362 low dose cohort

    Participants receive low dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection.

    Drug: IBI362 · Drug: Placebo · Drug: Dulaglutide

  • Experimental
    IBI362 medium dose cohort

    Participants receive medium dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection

    Drug: IBI362 · Drug: Placebo · Drug: Dulaglutide

  • Experimental
    IBI362 high dose cohort

    Participants receive high dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection

    Drug: IBI362 · Drug: Placebo · Drug: Dulaglutide

Interventions

  • DrugIBI362

    Administrated by subcutaneous injection

  • DrugPlacebo

    Administrated by subcutaneous injection

  • Administrated by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. To assess the number and incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of IBI362 compared with placebo

    Number of subjects with treatment emergent adverse events and serious adverse events through the end of the follow-up period

    Time frame: From the first dose of study drug to week 19

Secondary outcomes

  1. The PK/PD parameters of IBI362 in patients with T2DM

    Time frame: From Baseline to week 12

  2. Evaluate the Peak Plasma Concentration (Cmax) of IBI362 in patients with T2DM

    Time frame: From Baseline to week 12

  3. Evaluate the Area under the plasma concentration versus time curve (AUC) of IBI362 in patients with T2DM

    Time frame: From Baseline to week 12

  4. Evaluate the Fasting Blood Glucose (FBG ) of IBI362 in patients with T2DM

    Time frame: From Baseline to week 12

  5. Evaluate the Glucagon of IBI362 in patients with T2DM

    Time frame: From Baseline to week 12

  6. Evaluate the Insulin of IBI362 in patients with T2DM

    Time frame: From Baseline to week 12

  7. Evaluate the C-peptide of IBI362 in patients with T2DM

    Time frame: From Baseline to week 12

  8. Number of Participants With Anti-IBI362 Antibodies

    Serum samples will be analyzed by an electrochemiluminescence (ECL)-based immunoassay for anti-IBI362 binding antibodies. Positive samples will be subsequently tested in a receptor-ligand binding bioassay for anti-IBI362 neutralizing antibodies.

    Time frame: From the first dose of study drug to week 19

07

Study locations

1 site
  • China Japan Friendship Hospital
    Beijing, China
08

References and documents

Publications

  • Jiang H, Pang S, Zhang Y, Yu T, Liu M, Deng H, Li L, Feng L, Song B, Han-Zhang H, Ma Q, Qian L, Yang W. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022 Jun 24;13(1):3613. doi: 10.1038/s41467-022-31328-x. PubMed 35750681 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in May 2021, 8 months.

Of 41 phase 1/2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 71. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2020
First posted
Jul 10, 2020
StartActual
Sep 12, 2020
Primary completionActual
May 28, 2021
CompletionActual
May 28, 2021
Last update
Jul 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04466904
Responsible party
Sponsor
First posted
Jul 10, 2020
Start date
Sep 12, 2020
Primary completion
May 28, 2021
Completion
May 28, 2021
Last update
Jul 23, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion